WO2006004076A1 - Matière bio physiologiquement active - Google Patents
Matière bio physiologiquement active Download PDFInfo
- Publication number
- WO2006004076A1 WO2006004076A1 PCT/JP2005/012292 JP2005012292W WO2006004076A1 WO 2006004076 A1 WO2006004076 A1 WO 2006004076A1 JP 2005012292 W JP2005012292 W JP 2005012292W WO 2006004076 A1 WO2006004076 A1 WO 2006004076A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- silk
- protein
- bioactive
- biomaterial
- silkworm
- Prior art date
Links
- 239000012620 biological material Substances 0.000 title claims abstract description 72
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 117
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 107
- 241000255789 Bombyx mori Species 0.000 claims abstract description 79
- 230000009261 transgenic effect Effects 0.000 claims abstract description 37
- 239000002157 polynucleotide Substances 0.000 claims abstract description 25
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 25
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 25
- 235000018102 proteins Nutrition 0.000 claims description 102
- 230000000975 bioactive effect Effects 0.000 claims description 77
- 102000037865 fusion proteins Human genes 0.000 claims description 41
- 108020001507 fusion proteins Proteins 0.000 claims description 41
- 238000000034 method Methods 0.000 claims description 22
- 239000000872 buffer Substances 0.000 claims description 14
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims description 11
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims description 11
- 229940126864 fibroblast growth factor Drugs 0.000 claims description 11
- 239000003398 denaturant Substances 0.000 claims description 6
- 230000004927 fusion Effects 0.000 claims description 6
- 230000001766 physiological effect Effects 0.000 claims description 5
- 235000004252 protein component Nutrition 0.000 claims description 5
- 230000001172 regenerating effect Effects 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- 101710145505 Fiber protein Proteins 0.000 claims 1
- 230000035479 physiological effects, processes and functions Effects 0.000 claims 1
- 108010022355 Fibroins Proteins 0.000 abstract description 17
- 230000000694 effects Effects 0.000 abstract description 11
- 239000000243 solution Substances 0.000 description 43
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 32
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 32
- 239000000835 fiber Substances 0.000 description 24
- 101001052035 Homo sapiens Fibroblast growth factor 2 Proteins 0.000 description 23
- 239000013598 vector Substances 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 18
- 239000007864 aqueous solution Substances 0.000 description 15
- 235000013601 eggs Nutrition 0.000 description 14
- 210000004907 gland Anatomy 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- 230000004071 biological effect Effects 0.000 description 11
- 239000002299 complementary DNA Substances 0.000 description 11
- 239000002609 medium Substances 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 9
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 239000000499 gel Substances 0.000 description 8
- 230000017423 tissue regeneration Effects 0.000 description 8
- 210000003556 vascular endothelial cell Anatomy 0.000 description 8
- 230000010261 cell growth Effects 0.000 description 7
- 238000000502 dialysis Methods 0.000 description 7
- 239000013600 plasmid vector Substances 0.000 description 7
- 238000011069 regeneration method Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 6
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 6
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 6
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 6
- 102000014429 Insulin-like growth factor Human genes 0.000 description 6
- 108010025020 Nerve Growth Factor Proteins 0.000 description 6
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 6
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 6
- 108010009583 Transforming Growth Factors Proteins 0.000 description 6
- 102000009618 Transforming Growth Factors Human genes 0.000 description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 6
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 6
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 102000003390 tumor necrosis factor Human genes 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 5
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 5
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 5
- 102000015696 Interleukins Human genes 0.000 description 5
- 108010063738 Interleukins Proteins 0.000 description 5
- 102000015336 Nerve Growth Factor Human genes 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 210000002744 extracellular matrix Anatomy 0.000 description 5
- 210000002950 fibroblast Anatomy 0.000 description 5
- 230000003100 immobilizing effect Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 229940053128 nerve growth factor Drugs 0.000 description 5
- 230000007935 neutral effect Effects 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 210000003954 umbilical cord Anatomy 0.000 description 5
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 5
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 4
- 108010013296 Sericins Proteins 0.000 description 4
- 108700019146 Transgenes Proteins 0.000 description 4
- 108010020764 Transposases Proteins 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 239000004202 carbamide Substances 0.000 description 4
- 210000000349 chromosome Anatomy 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 108010021843 fluorescent protein 583 Proteins 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 239000012460 protein solution Substances 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 3
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102400001368 Epidermal growth factor Human genes 0.000 description 3
- 101800003838 Epidermal growth factor Proteins 0.000 description 3
- 102000003951 Erythropoietin Human genes 0.000 description 3
- 108090000394 Erythropoietin Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000000020 Nitrocellulose Substances 0.000 description 3
- 102000008579 Transposases Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 230000024245 cell differentiation Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 229940116977 epidermal growth factor Drugs 0.000 description 3
- 229940105423 erythropoietin Drugs 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- ZJZXSOKJEJFHCP-UHFFFAOYSA-M lithium;thiocyanate Chemical compound [Li+].[S-]C#N ZJZXSOKJEJFHCP-UHFFFAOYSA-M 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000000520 microinjection Methods 0.000 description 3
- 229920001220 nitrocellulos Polymers 0.000 description 3
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 239000012557 regeneration buffer Substances 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 229940034586 silk sericin Drugs 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 210000003606 umbilical vein Anatomy 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 101710163595 Chaperone protein DnaK Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 2
- 102100035308 Fibroblast growth factor 17 Human genes 0.000 description 2
- 108010053070 Glutathione Disulfide Proteins 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 description 2
- 101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 description 2
- 102100030703 Interleukin-22 Human genes 0.000 description 2
- 108010082093 Placenta Growth Factor Proteins 0.000 description 2
- 102100035194 Placenta growth factor Human genes 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 229940112869 bone morphogenetic protein Drugs 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 230000021164 cell adhesion Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 108091006047 fluorescent proteins Proteins 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- AMXOYNBUYSYVKV-UHFFFAOYSA-M lithium bromide Chemical compound [Li+].[Br-] AMXOYNBUYSYVKV-UHFFFAOYSA-M 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 108010054624 red fluorescent protein Proteins 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- -1 sheet Substances 0.000 description 2
- JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 229930183010 Amphotericin Natural products 0.000 description 1
- QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 description 1
- 241000255794 Bombyx mandarina Species 0.000 description 1
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 1
- 108010049951 Bone Morphogenetic Protein 3 Proteins 0.000 description 1
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 description 1
- 108010049976 Bone Morphogenetic Protein 5 Proteins 0.000 description 1
- 108010049974 Bone Morphogenetic Protein 6 Proteins 0.000 description 1
- 108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 description 1
- 102100028726 Bone morphogenetic protein 10 Human genes 0.000 description 1
- 101710118482 Bone morphogenetic protein 10 Proteins 0.000 description 1
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 1
- 102100024504 Bone morphogenetic protein 3 Human genes 0.000 description 1
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 1
- 102100022526 Bone morphogenetic protein 5 Human genes 0.000 description 1
- 102100022525 Bone morphogenetic protein 6 Human genes 0.000 description 1
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 description 1
- 102100022545 Bone morphogenetic protein 8B Human genes 0.000 description 1
- 101710117970 Bone morphogenetic protein 8B Proteins 0.000 description 1
- 102100037597 Brain-derived neurotrophic factor Human genes 0.000 description 1
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108090000569 Fibroblast Growth Factor-23 Proteins 0.000 description 1
- 102100028412 Fibroblast growth factor 10 Human genes 0.000 description 1
- 108090001047 Fibroblast growth factor 10 Proteins 0.000 description 1
- 108050003237 Fibroblast growth factor 11 Proteins 0.000 description 1
- 102100028413 Fibroblast growth factor 11 Human genes 0.000 description 1
- 108050003239 Fibroblast growth factor 12 Proteins 0.000 description 1
- 102100028417 Fibroblast growth factor 12 Human genes 0.000 description 1
- 108090000046 Fibroblast growth factor 14 Proteins 0.000 description 1
- 102000003685 Fibroblast growth factor 14 Human genes 0.000 description 1
- 108050002072 Fibroblast growth factor 16 Proteins 0.000 description 1
- 102100035307 Fibroblast growth factor 16 Human genes 0.000 description 1
- 108050002074 Fibroblast growth factor 17 Proteins 0.000 description 1
- 102100031734 Fibroblast growth factor 19 Human genes 0.000 description 1
- 108050002085 Fibroblast growth factor 20 Proteins 0.000 description 1
- 102100031361 Fibroblast growth factor 20 Human genes 0.000 description 1
- 108090000376 Fibroblast growth factor 21 Proteins 0.000 description 1
- 102000003973 Fibroblast growth factor 21 Human genes 0.000 description 1
- 108050002062 Fibroblast growth factor 22 Proteins 0.000 description 1
- 102100024804 Fibroblast growth factor 22 Human genes 0.000 description 1
- 102100024802 Fibroblast growth factor 23 Human genes 0.000 description 1
- 108090000378 Fibroblast growth factor 3 Proteins 0.000 description 1
- 102100028043 Fibroblast growth factor 3 Human genes 0.000 description 1
- 102100028072 Fibroblast growth factor 4 Human genes 0.000 description 1
- 108090000381 Fibroblast growth factor 4 Proteins 0.000 description 1
- 108090000380 Fibroblast growth factor 5 Proteins 0.000 description 1
- 102100028073 Fibroblast growth factor 5 Human genes 0.000 description 1
- 108090000382 Fibroblast growth factor 6 Proteins 0.000 description 1
- 102100028075 Fibroblast growth factor 6 Human genes 0.000 description 1
- 102100028071 Fibroblast growth factor 7 Human genes 0.000 description 1
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 1
- 108090000368 Fibroblast growth factor 8 Proteins 0.000 description 1
- 102100037680 Fibroblast growth factor 8 Human genes 0.000 description 1
- 102100037665 Fibroblast growth factor 9 Human genes 0.000 description 1
- 108090000367 Fibroblast growth factor 9 Proteins 0.000 description 1
- 101710124870 Fibroin light chain Proteins 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 108010090290 Growth Differentiation Factor 2 Proteins 0.000 description 1
- 102100040898 Growth/differentiation factor 11 Human genes 0.000 description 1
- 101710194452 Growth/differentiation factor 11 Proteins 0.000 description 1
- 102100040892 Growth/differentiation factor 2 Human genes 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000846394 Homo sapiens Fibroblast growth factor 19 Proteins 0.000 description 1
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 1
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 108090000177 Interleukin-11 Proteins 0.000 description 1
- 102100030698 Interleukin-12 subunit alpha Human genes 0.000 description 1
- 101710194995 Interleukin-12 subunit alpha Proteins 0.000 description 1
- 102100036701 Interleukin-12 subunit beta Human genes 0.000 description 1
- 101710187487 Interleukin-12 subunit beta Proteins 0.000 description 1
- 102000013691 Interleukin-17 Human genes 0.000 description 1
- 108050003558 Interleukin-17 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 108010002335 Interleukin-9 Proteins 0.000 description 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
- 241001024304 Mino Species 0.000 description 1
- 101100018424 Mus musculus Ids gene Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 108010059712 Pronase Proteins 0.000 description 1
- 239000012722 SDS sample buffer Substances 0.000 description 1
- 241000555745 Sciuridae Species 0.000 description 1
- 108010073925 Vascular Endothelial Growth Factor B Proteins 0.000 description 1
- 108010073919 Vascular Endothelial Growth Factor D Proteins 0.000 description 1
- 102100038217 Vascular endothelial growth factor B Human genes 0.000 description 1
- 102100038234 Vascular endothelial growth factor D Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 229940009444 amphotericin Drugs 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- XMQFTWRPUQYINF-UHFFFAOYSA-N bensulfuron-methyl Chemical compound COC(=O)C1=CC=CC=C1CS(=O)(=O)NC(=O)NC1=NC(OC)=CC(OC)=N1 XMQFTWRPUQYINF-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical group OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003196 chaotropic effect Effects 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000000385 dialysis solution Substances 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 108090000047 fibroblast growth factor 13 Proteins 0.000 description 1
- 108090000370 fibroblast growth factor 18 Proteins 0.000 description 1
- 102000003977 fibroblast growth factor 18 Human genes 0.000 description 1
- 239000002657 fibrous material Substances 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229960000789 guanidine hydrochloride Drugs 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 108090000681 interleukin 20 Proteins 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 239000012474 protein marker Substances 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002265 redox agent Substances 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 108010064995 silkworm fibroin Proteins 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/033—Rearing or breeding invertebrates; New breeds of invertebrates
- A01K67/0333—Genetically modified invertebrates, e.g. transgenic, polyploid
- A01K67/0337—Genetically modified Arthropods
- A01K67/0339—Genetically modified insects, e.g. Drosophila melanogaster, medfly
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
- C07K14/43586—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from silkworms
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Definitions
- the invention of this application relates to a biomaterial having a given physiological activity. More specifically, the invention of this application includes a transgenic silkworm that produces a silk protein containing a fusion protein of silk hive mouth-in and a physiologically active substance, and a silk protein produced by the silkworm or the fusion protein as a main component. It relates to bioactive biomaterials.
- Biological tissues are composed of cells and extracellular matrix, and cells carry out various physiological phenomena including adhesion, proliferation and differentiation using the extracellular matrix as a scaffold.
- the extracellular matrix In the case of damage to living tissue, if the extracellular matrix is not present, the repair and regeneration of the tissue will not be successful because the damaged area and its surrounding cells will not adhere, proliferate or differentiate rapidly. . Therefore, when a living tissue is largely deficient, an extracellular matrix must be provided from the outside to the target tissue that is the deficient site. Therefore, what is needed as a substitute for the extracellular matrix is biomaterial that has an affinity for organisms.
- Bioactive proteins such as cell growth factors and cytokines that promote cell growth and differentiation play an extremely important role in tissue repair and regeneration.
- Human basic fibroblast growth factor (bFGF) acts at a low concentration on not only fibroblasts but also a wide range of cells such as vascular endothelial cells, osteoblasts, and nerve cells to promote tissue repair and regeneration. Therefore, an attempt has been made to supply these physiologically active proteins from the outside to the damaged site to repair and accelerate regeneration. However, if the supplied bioactive protein is at a low concentration in the target tissue, tissue repair / regeneration does not proceed quickly.
- Non-patent Document 1 When an aqueous solution of bFGF is administered to a target tissue, about half of the dose administered in only 4 hours is lost due to diffusion (Non-patent Document 1).
- Silk hive mouth-in is the main protein that constitutes about 70% of silk thread spouted by silkworms.
- Silk fiber mouth-in is a natural material and has been used as a material that can be implanted into the body of surgical sutures for many years because it has excellent operability and biocompatibility. .
- silk fiproin has been liquefied in water and methods for producing films and gels using it have been developed, and the potential for use as new biomaterials is expanding.
- Non-patent Document 2 a support for cell culture using a silk-fibre mouth-in film
- Patent Document 3 wound skin materials
- Patent Document 3 contact lenses
- Non-patent Document 3 silk fibroin films have been shown to be digested by protease XIV collagenase IA under physiological conditions. It has been suggested that mouth-in has biocompatibility and biodegradability.
- Non-patent document 4 integrin recognition sequence (RGD) (Non-patent document 4) and ⁇ -galactose residue (Non-patent document 5) specifically recognized by hepatocyte surface
- RGD integrin recognition sequence
- Non-patent document 5 ⁇ -galactose residue
- Non-Patent Document 6 As a material that promotes tissue repair and regeneration by immobilizing bioactive proteins such as cell growth factors and cytokines that promote cell growth and differentiation to biomaterials such as chitosan film through chemical covalent bonds Attempts to use it have been made (Non-Patent Document 6). At this time, purified recombinant protein derived from E. coli or insect cells is used as the physiologically active protein used for immobilization. Therefore, a biomaterial in which a physiologically active protein is immobilized cannot be produced unless complicated steps such as expression, purification, and immobilization of the recombinant protein are performed. In addition, in order for this immobilized bioactive protein to exhibit high biological activity, it is necessary to immobilize a relatively large amount of recombinant protein.
- the quantitative problem of the physiologically active protein to be immobilized is the biggest problem in producing a biomaterial containing a physiologically active protein. This is because in the process of chemical immobilization, the biological activity of the bioactive protein decreases due to heating or contact with an organic solvent.
- Transgenic silkworm The applicants of the present invention have invented and have applied for a patent for a transgenic silkworm that produces recombinant human collagen as part of a silk protein (Patent Document 4). In addition, a method for producing a recombinant cytokine using a transgenic silkworm has been devised (Patent Document 5). Thus, silkworms are attracting attention as host animals for producing recombinant proteins.
- Patent Document 1 Japanese Patent Laid-Open No. 1-243948
- Patent Document 2 JP-A-11-70160
- Patent Document 3 Japanese Patent Laid-Open No. 1-52303
- Patent Document 4 Japanese Patent Laid-Open No. 2004-16144
- Patent Document 5 Japanese Patent Laid-Open No. 2003-325188
- Non-Patent Document 1 J. Biomed. Mater. Res. 64A, 177-181 (2003)
- Non-Patent Document 2 J. Biomed. Mater. Res. 29, 1215-1221 (1995)
- Non-Patent Document 3 Biomaterials 24, 357-365 (2003)
- Non-Patent Document 4 J. Biomed. Mater. Res. 54, 139-148 (2001)
- Non-Patent Document 5 Biomaterials 25, 1 13 1- 1 140 (2004)
- Non-Patent Document 6 J Biomed. Mater. Res. 64Ai l), 177-181 (2003)
- biomaterials to which bioactive proteins are immobilized are large as medical materials due to two effects such as “bioactivity” of the protein and “biocompatibility” of the biomaterial. It has potential.
- bioactive proteins and biomaterials were prepared separately and combined to create them.
- Another problem is that the activity of the immobilized physiologically active protein is decreasing.
- the invention of this application has been made in view of the problems of the prior art as described above, and is a novel material that can easily obtain a biomaterial containing a biologically active protein that retains activity and function. The problem is to provide means.
- This application is obtained from a transgenic silkworm having a fusion polynucleotide encoding a fusion protein of silk fibroin and a physiologically active protein in the genome as a first invention for solving the above-mentioned problems.
- a bioactive biomaterial mainly composed of a recombinant silk protein containing the fusion protein.
- this application is a recombinant silk protein obtained from a transgenic silkworm that possesses a fusion polynucleotide encoding a fusion protein of silk fiber mouth-in and a physiologically active protein in the genome. From the above, a bioactive biomaterial from which one or more protein components other than the fusion protein are removed is provided.
- a transgene which has a fusion polynucleotide encoding a fusion protein of silk fiber mouth-in and a physiologically active protein in its genome, and produces a recombinant silk protein containing the fusion protein.
- the physiologically active protein is a human fibroblast growth factor.
- This application provides, as a fourth invention, a silk thread or a protein in the silk line produced by the transgenic silkworm of the third invention.
- This application provides, as a fifth invention, a bioactive biomaterial solution obtained by treating a silk thread produced by the transgenic silkworm of the third invention with a solubilizing agent.
- This application provides, as a sixth invention, a method for regenerating the physiological activity of the bioactive biomaterial solution of the fifth invention, wherein the bioactive biomaterial solution is treated with a denaturant, and then in the bioactive biomaterial solution. There is provided a method characterized by reducing the concentration of the denaturant.
- This application provides, as a seventh invention, a bioactive biomaterial processed product molded using the bioactive biomaterial of the first invention or the second invention.
- physiologically active protein means a protein having at least one known function that acts on physiological functions of animals and plants including humans.
- Fusion protein means that the silk fiber mouth-in and the physiologically active protein are physically fused and do not separate by operation in the normal use range.
- the fusion protein in the present invention also means that the silk fiber mouth-in and the physiologically active protein are bound in a state that retains the function and activity corresponding to each purpose of use.
- “recombinant silk protein including fusion protein” specifically means a protein component of silk produced by transgene silkworm or a protein in the lumen of silk gland.
- the term “main component” means, for example, silk thread or silk thread, as long as the function of the bioactive biomaterial of the present invention is substantially carried by the fusion protein contained in the recombinant silk protein. It means that a small amount of reagent or the like used for separating the protein component from the glandular lumen may remain.
- a bioactive biomaterial containing a fusion protein of silk hive mouth-in and a bioactive protein can be obtained as a recombinant silk protein produced by a transgene silkworm. Therefore, in the conventional method, the operations for securing and immobilizing individual purified recombinant proteins, which were necessary for immobilizing the bioactive protein to silk fibroin, are omitted. Furthermore, since no heating or treatment with an organic solvent is required, the activity of the bioactive protein is not impaired.
- FIG. 1 shows the expression of a fusion protein between silk hive mouth-in and human bFGF in silkworm silk of Transgenic silkworm.
- Figure A shows the result of Kumashi staining of SDS polyacrylamide gel developed from silk-five mouth-in samples prepared from silkworms of wild-type silkworm and transgenic silkworm.
- Figure B shows the results of immunoblot analysis of the nitrocellulose membrane to which the protein developed on SDS polyacrylamide gel was transferred with anti-human bFGF polyclonal antibody.
- Lane M contains a protein marker
- Lane W contains a silkworm silk-in sample of a wild-type silkworm
- Lanes 1 and 2 contain silky silkworms of different transgenic silkworms.
- FIG. 1 shows the biological activity of silk hive mouth-in solution containing human bFGF prepared from silkworm silk of transgenic silkworm. It is the result of investigating the biological activity of silk fibroin solution containing human bFGF quantitatively using WST-1 method. Below each column of the graph is the concentration of human bFGF in the silk hive mouth-in solution added to the medium.
- the column shows 100% growth of human umbilical vascular endothelial cells when cultured in normal medium (containing 5 ng / ml human recombinant bFGF), and human umbilical vascular endothelial cells in medium without bFGF.
- the figure shows the relative growth of the cells when the cells are cultured with the silk fib-in solution added to the medium without bFGF, assuming that the growth of the cells when cultured is 0%.
- proliferation of umbilical cord vascular endothelial cells by human bFGF in silk-fibre mouth-in solution was similarly performed by adding human recombinant bFGF expressed in E.
- FIG. 4 is a structural diagram of the vector pL-bFGF prepared in the example.
- DsRed red fluorescent protein
- a polynucleotide encoding a fusion protein of silk fibroin and bFGF is incorporated.
- Transgenic silkworms can be produced by introducing a polynucleotide encoding a fusion protein of a physiologically active protein and silk fib-in into the silkworm chromosome.
- Silk hive mouth-in is a protein complex in which a hive chain in H chain with a molecular weight of 350 kDa and a hive in L chain with a molecular weight of 25 kDa are associated, and the polynucleotide encoding them is known (the hive in H chain : GenBank Accession No. AF226688; Five mouth in L chain: GenBank Accession No. M76430).
- a polynucleotide encoding a biologically active protein is linked to either a polynucleotide encoding a hive mouth-in H chain or a hive mouth-in L chain.
- the ligation position of the polynucleotide encoding the biologically active protein may be 5 ′ side or 3 ′ J of the polynucleotide encoding the five mouth in H chain or fiproin L chain.
- the polynucleotides may be directly linked or indirectly linked via a linker.
- the polynucleotide encoding the hive mouth-in H chain or the hive mouth-in L chain may be a sequence encoding the full length of each protein or a partial sequence.
- Bioactive proteins fused with silk hive mouth-in refer to a group of proteins that exhibit various physiological activities on cells.
- FGF fibroblast growth factor
- MBP bone morphogenetic factor
- EGF epidermal growth factor
- PDGF platelet-derived growth factor
- TGF insulin-like growth factor
- IGF insulin-like growth factor
- HGF hepatocyte growth factor
- VEGF vascular endothelial growth factor
- NNF nerve growth factor
- interleukins This refers to cytosines including IDs, erythropoietin, colony stimulating factor (CSF), tumor necrosis factor (TNF), etc.
- FGF Fibroblast growth factor
- FGF-3 Fibroblast growth factor-3
- X14445, FGF-4 J02986, FGF-5; M37825, FGF-6; X63454, FGF-7; M60828, FGF-8 AH006649, FGF-9; D 14838, FGF-10; AF411527, FGF-11; AY049782, FGF-12; U66197, FGF-13; U66198, FGF-14; U66200, FGF-16; AB009391, FGF-17; AB009249, FGF-18; AF075292, FGF-19; AFl 10400, FGF-20; AB044277, FGF-21; AY359086, FGF-22; AB021925, FGF-23; AF263537, etc. Osteogenic factors
- BMP (Bone morphogenetic protein) -1; M22488, BMP-2; M22489, BMP-3; M22491, BMP-4; U43842, BMP-5; M60314, BMP-6; M60315, BMP-7; X51801, BMP-8B M97016, BMP-9; AF188285, BMP-10; AF101441, BMP-11; AFl 00907, etc.
- EGF Epidermal growth factor
- EGF Epidermal Growth Factor
- X04571 X04571, etc.
- PDGF Plate-derived growth factor
- PDGF-A PDGF (Platelet-derived growth factor)
- PDGF-B PDGF-B
- TGF Transforming growth factor
- TGF Transforming growth factor
- IGF Insulin-like growth factor
- IGF Insulin-like growth factor
- HGF Hepatocyte growth factor
- HGF Hepatocyte growth factor
- VEGF Vascular endothelial growth factor
- VEGF Vascular endothelial growth factor
- M32977 VEGF-B
- U52819 VEGF- C
- X94216 VEGF-D
- AJ000185 PIGF (Placenta growth factor); X54936, etc.
- NGF Nema growth factor
- X52599BDNF Brain-derived neurotrophic factor
- Interleukin (IL) class class 1
- IL Interleukin-1 alpha; M28983, IL-1 beta; M 15330, IL-2; U25676, I 3; M14743, IL-4; M13982, IL-5; X04688, IL-6; M29150, L- 7; J04156, IL-8; M26383, IL-9; AF361105, IL-10; M57627, IL-11; M57765, IL-12A; M65291, IL-12B; M65290, IL-13; L06801, IL-15; U14407, IL-16; M90391, IL-17; U32659, IL-18; AY044641, IL-19; AY040367, IL-20; AF212311, IL-21; AF254069, IL-22; AF279437, etc. )
- EPO Errythropoietin
- Ml 1319 Ml 1319, etc.
- GM Granulocyte macrophage
- M 1220 G (Granulocyte) -CSF
- G G (Granulocyte) -CSF
- M 17706 M (Macrophage) -CSF
- M27087 etc.
- Tumor necrosis factor (TNF) TNF
- the polynucleotide and the polynucleotide encoding the bioactive protein are linked by genetic engineering techniques.
- the polynucleotide encoding the fusion protein may be a fib mouth in H chain, L chain or P25. It needs to be linked downstream of the silk protein gene-derived promo. In order to increase the transcriptional activity of these promoters, an enhancer may be further linked.
- the enhancer may be derived from a silk protein gene or from a protein other than a silk protein gene. Moreover, it may be derived from silkworms, or may be derived from other animals or viruses. In this way, a fusion protein expression cassette is constructed. This expression cassette is then inserted into a vector to create a transgenic silkworm. Any vector may be used as long as it can insert a foreign gene into the silkworm chromosome. For example, a vector prepared based on a DNA-type transposon can be used. is there. So far, DNA-type transposons that have been shown to have gene transfer activity into the silkworm chromosome include piggyBac and Mariner> Minos.
- the vector using piggyBac is actually transgeneic silkworm by Tamura et al. (Nat. Biotechnol. 18, 81-84 (2000)) Nyota (Nat. Biotechnol. 21, 52-56 (2003)) et al. Is used to create Use a vector created based on DiggyBac In this case, for example, a method similar to the method of Tamura et al. (Nat. Biotechnol. 18, 81-84, 2000) may be used.
- a pair of inverted repetitive sequences of piggyBac are incorporated into an appropriate plasmid vector, and a polynucleotide encoding a fusion protein and a promoter are inserted into a region sandwiched between the inverted repetitive sequences in this vector.
- This plasmid vector is microinjected into silkworm eggs together with a piggyBac transposase expression vector (helper plasmid).
- helper plasmid is a recombinant plasmid vector lacking one or both of the piggyBac inverted repeats and essentially incorporating only the piggyBac transposase gene region.
- the promoter for expressing the transposase may be the endogenous transposase promoter, or the silkworm / actin promoter or the Drosophila HSP70 promoter. May be used.
- the marker gene can be incorporated at the same time in the vector in which the polynucleotide to be inserted is incorporated.
- a promoter sequence such as a silkworm-actin promoter or a Drosophila HSP70 promoter is incorporated upstream of the marker gene, and the marker gene is expressed by its action. As described above, F0 larvae hatched from silkworm eggs microinjected with Vector 1 are raised.
- This F0 silkworm is crossed with a sibling or wild-type silkworm, and a transgenic silkworm is screened from the next-generation (F1 generation) silkworm.
- the marker gene is integrated in the vector, screening is performed using the phenotype.
- screening can be performed by irradiating F1 generation silkworm eggs and larvae with excitation light and detecting the fluorescence emitted by the fluorescent protein.
- PCR can be screened by Southern blotting using genomic DNA extracted from larvae and silkworm pupae.
- transgenic silkworm the polynucleotide encoding the fusion protein is stably integrated into the chromosome and is not lost even in its offspring.
- Transgenic silkworms that have a polynucleotide encoding a fusion protein of silk fiproin and a bioactive protein synthesize a recombinant fusion protein in the silk gland at the age of five. Since this recombinant fusion protein has a part of the amino acid sequence of silk fiber mouth-in, it forms a complex with the endogenous silk protein, and the silk gland lumen from the silk gland cells together with the endogenous silk protein. Secreted into the body.
- Liquid silk fibroin containing recombinant fusion protein secreted into the lumen becomes silk thread when spited, and silkworms form cocoons with the silk thread.
- the bioactive biomaterial (recombinant silk protein) of the present invention is recovered from the liquid silk protein accumulated in the silk gland lumen, it can be obtained, for example, by the following method. Cut the body of Transgenic silkworm the day before spitting silk thread, take out the silk gland, and cut and collect only the rear silk gland. The collected posterior silk gland is cut into pieces of about 5 mm and soaked in distilled water for about 4 hours. Thereafter, tissue pieces of the posterior silk gland are removed by tweezers or removed by light centrifugation.
- a recombinant silk protein (bioactive biomaterial) containing a fusion protein of a bioactive protein and a silk fiber mouth can be prepared as an aqueous solution.
- the silk thread spun by Transgenic Silkworm itself becomes a bioactive biomaterial.
- the silk thread of Transgenic silkworm can be made into a bioactive biomaterial solution (for example, an aqueous solution) by treating the silk thread with a solubilizing agent, for example.
- chaotropic salts such as 9 M lithium thiocyanate and lithium bromide
- (Ratio 1: 8: 2) (Nissan 6 1 2, 91 -94 (1998)) can be used.
- the silk thread is solubilized in these solubilizers by soaking for 10 to 48 hours, preferably 18 to 36 hours, particularly preferably about 24 hours.
- this aqueous solution can be prepared as a bioactive biomaterial aqueous solution by dialysis with distilled water or the like.
- bioactive biomaterial solution In the process of isolating silk fiber lumen protein (bioactive biomaterial solution) or in the process of preparing bioactive biomaterial solution from silk thread, the bioactive protein is denatured and its biological activity is lost or reduced.
- a bioactive biomaterial solution is treated with a denaturing agent, and then the biological activity of the bioactive protein is regenerated by reducing the concentration of the denaturing agent in the bioactive biomaterial solution, thereby A physiologically active biomaterial aqueous solution containing a physiologically active protein can also be obtained.
- a silk protein solution from a liquid silk protein or silk thread is dissolved in a buffer solution containing a denaturing agent (for example, high-concentration urea-guanidine hydrochloride, etc.) to make a completely denatured silk protein solution.
- a denaturing agent for example, high-concentration urea-guanidine hydrochloride, etc.
- dialysis and dilution are performed stepwise to denature the silk protein solution. Decrease the concentration of the agent little by little. That is, the final concentration of the modifier is 5% or less, preferably 3% or less, particularly preferably 1% or less.
- the biologically active protein in the silk protein solution is refolded from a completely denatured state to the correct body structure, so that the biological activity of the biologically active protein is regenerated.
- the above method is an example for regenerating a physiologically active protein, and the optimum conditions for efficiently regenerating a physiologically active protein vary depending on the type of the physiologically active protein. Therefore, in order to obtain a bioactive biomaterial solution containing an active recombinant fusion protein, it is important to correctly and efficiently regenerate various bioactive proteins under optimal conditions. For example, the regeneration buffer used for dialysis and dilution needs to be carefully examined in terms of pH, temperature, ionic strength, presence of reducing agent, etc., depending on the type of bioactive protein.
- one or more protein components other than the fusion protein may be removed from the recombinant silk protein obtained as described above or a solution thereof.
- silk thread produced by silkworm mainly contains fib mouth in, P25 and sericin.
- the bioactive biomaterial of the present invention is a silk thread or silk wire tamper containing a physiologically active protein. Proteins other than fib mouth-in (P25 and Z or sericin) may be removed from the protein.
- sericin is known to have antigenicity to the human body, it is preferable to remove sericin when the bioactive biomaterial is applied directly to the human body.
- aqueous solution such as 0.3-0.5% aqueous sodium bicarbonate or soapy water, or an 8 M urea aqueous solution.
- a method of heating at 80 at a protein denaturant aqueous solution or a method of digesting with an enzyme such as trypsin can be used.
- the silky bioactive biomaterial obtained in this way can be used as a powder material, for example, as a fibrous material or by pulverization using a homogenizer or the like.
- a liquid bioactive biomaterial obtained from the silk gland lumen or an aqueous bioactive biomaterial prepared from silk can be processed into a film, gel, or sponge.
- a bioactive film can be produced by pouring a bioactive biomaterial solution onto a flat plate and allowing it to air dry. In order to produce a stronger film, the film may be air-dried and then immersed in 90% (v / v) methanol / distilled water.
- films mainly composed of silk protein especially have adhesion and proliferation properties to fibroblasts and the like.
- biomaterial films are highly functional films with added physiological activities such as the proliferation and differentiation induction of cells with various physiologically active proteins.
- a bioactive biomaterial powder having an active bioactive protein function is prepared by desalting a bioactive biomaterial aqueous solution by dialysis against pure water and lyophilization. be able to.
- the pH of the silk fiber mouth-in aqueous solution is made weakly acidic using a citrate buffer solution or the like, so that Biomaterial gels can also be made.
- biologically active biomaterials it is not limited to these forms and methods, and various methods such as solution, sheet, gel, granule, and sponge can be used depending on the application. It can be processed into a shape.
- Example 1 The following is an example of a method for producing a bioactive biomaterial containing active human basic fibroblast growth factor (bFGF) using transgene silkworm silk thread. The invention will be described in detail, but the invention of this application is not limited to this embodiment.
- bFGF basic fibroblast growth factor
- pL-bFGF a vector that expresses a fusion protein of silk hive-in and human bFGF.
- the insert DNA contained in the pL-bFGF vector is composed of a silkworm silk fib-in L chain promoter, a silkworm silk fib in L chain cDNA, a human bFGF cDNA, and a silkworm silk fiproin L chain poly A addition signal sequence.
- the silk-fibre-in L chain promoter is a pLE vector (Nat. Biotechnol. 2 1, 52-56 (2003)), and is a primer with a restriction enzyme EcoRI recognition sequence at the 5 'end.
- the both ends of the obtained DNA fragment were cleaved with Pstl and BamHI and inserted between the Pstl site and BamHI site of pBluescriptIISK +
- the cDNA encoding human bFGF is The DNA fragment containing the sequence corresponding to nucleotide number 495-935 (GeneBank database accession number NM-002006) was obtained by PCR using human fibroblast cDNA as a saddle type.
- a cDNA encoding the fusion protein of bFGF and bFGF was prepared, and from this vector, the Pstl cytoplasm present at the 5 'end of the silk-fibre mouth-in L chain cDNA and the 3' end of human bFGF were present.
- the silk protein in L chain and bFGF fusion protein cDNA was excised, and the above-mentioned silk fiber in L chain promoter was incorporated. Of over and inserted between the Pstl site and EcoRI site at the 3 'end of the silk Fuiburoi down L chain promoter.
- Silkworm silk of this plasmid vector Using the EcoRI site located at the 5 'end of the hive mouth in light chain promotion and the 3' end of human bFGF, an insert DNA fragment consisting of the fibroin light chain promoter and the fusion protein cDNA was excised and pBac [3xP3- DsRed / pA] (Nat. Biotechnol. 21, 52-56 (2003)) was inserted into the EcoRI site upstream of the fiproin light chain poly A-added signal sequence. In this way, a plasmid vector for microinjection (pL-bFGF) was prepared (see FIG. 4).
- the pL-bFGF vector prepared in Example 1 was purified by the cesium chloride density gradient method, and this vector and helper plasmid pHA3PIG (Nat. Biotechnol. 18, 81-84). , 2000), and after ethanol precipitation, injection buffer solution (0.5 mM phosphate buffer pH 7.0, 5 niM KC1) was added so that the concentrations of pL-bFGF and pHA3PIG were 200 pg / ml respectively. ). A small amount of this DNA solution was injected at a volume of about 15-20 nl per egg into silkworm eggs at the preblastoderm stage 2-8 hours after laying. A total of 2423 eggs were microinjected.
- the silk thread produced by the transgenic silkworm obtained in Example 3 was pulverized using a homogenizer.
- the ground silk thread is suspended in a trypsin solution (0.5 mg / ml aqueous solution of trypsin dissolved in 50 mM Tris-HCl buffer pH 7.6) at a concentration of 5 mg / ml, and the silk thread is shaken.
- the silk sericin contained in the rice was erased. Thereafter, the silk fiber mouth-in was recovered by centrifugation, and the digested silk sericin was removed.
- the collected silk fiber mouth-in is washed thoroughly with a neutral buffer and then suspended in a mixed solution of 9 M lithium thiocyanate and 5% ⁇ -mercaptoethanol at a concentration of 5 mg / ml at 4 ° C. Dissolved by shaking. Then, the silk fiproin solution was recovered by removing the undissolved silk hive mouth in by centrifugation. This silk hive mouth-in solution was mixed with SDS-sample buffer, and the proteins contained in the solution were spread by SDS polyacrylamide gel electrophoresis and stained with Kumashi ( Figure 1A). The protein developed on the gel was transferred to a nitrocellulose membrane (PROTRAN) by a conventional method.
- PROTRAN nitrocellulose membrane
- This nitrocellulose membrane was treated with a blocking solution (5% Skim milk / 50 mM Tris-HCl buffer pH 7.5, 150 mM NaCl) at 4 for 16 hours, and then TBS (50 mM Tris-HCl buffer pH 7.5, 150 mM). It was reacted with an anti-human bFGF polyclonal antibody (R & D Systems, AF-233-NA) diluted 200-fold with NaCl) solution at room temperature for about 2 hours. Next, it was reacted with a peroxidase-labeled anti-goat IgG polyclonal antibody (VECTOR, PI-9500) diluted 3000 times with a blocking solution at room temperature for about 1 hour.
- a blocking solution 5% Skim milk / 50 mM Tris-HCl buffer pH 7.5, 150 mM NaCl
- TBS 50 mM Tris-HCl buffer pH 7.5, 150 mM
- 2x103 human umbilical vein endothelial cells were seeded in one well (diameter 6.4 mm) of a 96-well plate (Falcon) for tissue culture, and normal medium (2% wild fetal serum, 10 ng / ml EGF, lpg Vascular endothelial cell basal medium (Humedia-EB2 (KURABO)) containing 4 ml / ml hydrocortisone, 50 pg / ml gentamicin, 50 ng / ml amphotericin, lOpg / ml heparin, and 5 ng / ml human recombinant bFGF) for 4 hours Cultivated.
- normal medium 2% wild fetal serum, 10 ng / ml EGF, lpg Vascular endothelial cell basal medium (Humedia-EB2 (KURABO)
- the degree of growth per bFGF amount was equivalent to that of human recombinant bFGF expressed in E. coli used as a positive control. As described above, it was confirmed that the silk hive mouth-in solution containing bFGF prepared from silk has high biological activity.
- silk fibroin solution prepared from silkworm silk of wild-type silkworm and silk-fibre mouth-in solution in which human recombinant bFGF expressed in Escherichia coli was mixed with silk-type mouth silk-in solution of wild-type silkworm were also used.
- silk-fibre-in-film was prepared and seeded with human umbilical vein endothelial cells.
- the silk-fibre mouth-in material containing bFGF is useful as a functional biomaterial with added biological activities such as cell proliferation and differentiation.
- the invention of this application provides a bioactive biomaterial containing an active bioactive protein.
- This bioactive biomaterial By processing this bioactive biomaterial into films, sheets, gels, sponges, fibers, etc., new biomaterials that can be used in industrial fields such as medical care are provided.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Environmental Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Husbandry (AREA)
- Biochemistry (AREA)
- Insects & Arthropods (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Peptides Or Proteins (AREA)
- Materials For Medical Uses (AREA)
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004-194215 | 2004-06-30 | ||
JP2004194215A JP2006016323A (ja) | 2004-06-30 | 2004-06-30 | 生理活性バイオマテリアル |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006004076A1 true WO2006004076A1 (fr) | 2006-01-12 |
Family
ID=35782879
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/012292 WO2006004076A1 (fr) | 2004-06-30 | 2005-06-28 | Matière bio physiologiquement active |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP2006016323A (fr) |
WO (1) | WO2006004076A1 (fr) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9089525B1 (en) | 2011-07-01 | 2015-07-28 | Ngm Biopharmaceuticals, Inc. | Methods of using compositions comprising variants and fusions of FGF19 polypeptides for reducing glucose levels in a subject |
US9273107B2 (en) | 2012-12-27 | 2016-03-01 | Ngm Biopharmaceuticals, Inc. | Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
US9290557B2 (en) | 2012-11-28 | 2016-03-22 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides |
US9925242B2 (en) | 2012-12-27 | 2018-03-27 | Ngm Biopharmaceuticals, Inc. | Methods of using compositions comprising variants and fusions of FGF19 polypeptides for treatment of nonalcoholic steatohepatitis |
US9963494B2 (en) | 2012-11-28 | 2018-05-08 | Ngm Biopharmaceuticals, Inc. | Methods of using compositions comprising variants and fusions of FGF19 polypeptides for reducing glucose levels in a subject |
US10093735B2 (en) | 2014-01-24 | 2018-10-09 | Ngm Biopharmaceuticals, Inc. | Beta-klotho binding proteins |
US10369199B2 (en) | 2013-10-28 | 2019-08-06 | Ngm Biopharmaceuticals, Inc. | Methods of using variants of FGF19 polypeptides for the treatment of cancer |
US10398758B2 (en) | 2014-05-28 | 2019-09-03 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions |
US10434144B2 (en) | 2014-11-07 | 2019-10-08 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders |
US10456449B2 (en) | 2014-06-16 | 2019-10-29 | Ngm Biopharmaceuticals, Inc. | Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
US10517929B2 (en) | 2014-10-23 | 2019-12-31 | Ngm Biopharmaceuticals, Inc. | Pharmaceutical compositions comprising FGF19 variants |
US10744185B2 (en) | 2015-11-09 | 2020-08-18 | Ngm Biopharmaceuticals, Inc. | Methods of using variants of FGF19 polypeptides for the treatment of pruritus |
US10800843B2 (en) | 2015-07-29 | 2020-10-13 | Ngm Biopharmaceuticals, Inc. | Beta klotho-binding proteins |
US11370841B2 (en) | 2016-08-26 | 2022-06-28 | Ngm Biopharmaceuticals, Inc. | Methods of treating fibroblast growth factor 19-mediated cancers and tumors |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2064329A2 (fr) * | 2006-08-23 | 2009-06-03 | GEURTSEN, Werner K. | Matériaux nanocomposites de protéines adhésives à la biosilice : synthèse et application en dentisterie |
JP2008067612A (ja) * | 2006-09-12 | 2008-03-27 | Hiroshima Industrial Promotion Organization | 機能的な抗体分子を生産するトランスジェニックカイコ |
JP2008125366A (ja) * | 2006-11-16 | 2008-06-05 | Hiroshima Industrial Promotion Organization | トランスジェニックカイコの絹糸腺で組換えタンパク質を発現させるための融合ポリヌクレオチド |
JP5812256B2 (ja) * | 2011-05-20 | 2015-11-11 | 国立研究開発法人農業生物資源研究所 | 一本鎖抗体の製造方法 |
JP6362878B2 (ja) * | 2013-03-12 | 2018-07-25 | 国立研究開発法人農業・食品産業技術総合研究機構 | 改変ペプチド繰り返しペプチドを含む融合タンパク質および該融合タンパク質を含むシルク繊維 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04503607A (ja) * | 1989-02-24 | 1992-07-02 | イムノセラピューティックス・インコーポレイテッド | 固定化サイトカイン類 |
JPH11243948A (ja) * | 1998-03-02 | 1999-09-14 | Natl Inst Of Sericultural & Entomological Science | 動物細胞増殖用の細胞培養床基材及びその調製方法 |
JP2000510712A (ja) * | 1996-03-29 | 2000-08-22 | ハンソン,ハンス―アルネ | 生体組織の再生促進 |
JP2000336040A (ja) * | 1999-05-28 | 2000-12-05 | Univ Tokyo | 筋線維芽細胞系疾患の予防または治療剤 |
JP2003024056A (ja) * | 2001-06-06 | 2003-01-28 | Becton Dickinson & Co | すぐに使用できる均一に分散した細胞外マトリックスを基質に提供する方法 |
JP2004016144A (ja) * | 2002-06-18 | 2004-01-22 | Japan Science & Technology Corp | ヒト・コラーゲンを産生する形質転換カイコ |
FR2852325A1 (fr) * | 2003-03-13 | 2004-09-17 | Centre Nat Rech Scient | Acide nucleique dirigeant l'expression d'un polypeptide d'interet dans les glandes sericigenes posterieures d'un lepidoptere, et ses applications |
-
2004
- 2004-06-30 JP JP2004194215A patent/JP2006016323A/ja active Pending
-
2005
- 2005-06-28 WO PCT/JP2005/012292 patent/WO2006004076A1/fr active Application Filing
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04503607A (ja) * | 1989-02-24 | 1992-07-02 | イムノセラピューティックス・インコーポレイテッド | 固定化サイトカイン類 |
JP2000510712A (ja) * | 1996-03-29 | 2000-08-22 | ハンソン,ハンス―アルネ | 生体組織の再生促進 |
JPH11243948A (ja) * | 1998-03-02 | 1999-09-14 | Natl Inst Of Sericultural & Entomological Science | 動物細胞増殖用の細胞培養床基材及びその調製方法 |
JP2000336040A (ja) * | 1999-05-28 | 2000-12-05 | Univ Tokyo | 筋線維芽細胞系疾患の予防または治療剤 |
JP2003024056A (ja) * | 2001-06-06 | 2003-01-28 | Becton Dickinson & Co | すぐに使用できる均一に分散した細胞外マトリックスを基質に提供する方法 |
JP2004016144A (ja) * | 2002-06-18 | 2004-01-22 | Japan Science & Technology Corp | ヒト・コラーゲンを産生する形質転換カイコ |
FR2852325A1 (fr) * | 2003-03-13 | 2004-09-17 | Centre Nat Rech Scient | Acide nucleique dirigeant l'expression d'un polypeptide d'interet dans les glandes sericigenes posterieures d'un lepidoptere, et ses applications |
Cited By (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9580483B2 (en) | 2011-07-01 | 2017-02-28 | Ngm Biopharmaceuticals, Inc. | Methods of using compositions comprising variants and fusions of FGF19 polypeptides for treatment of diabetes |
US9670260B2 (en) | 2011-07-01 | 2017-06-06 | Ngm Biopharmaceuticals, Inc. | Compositions comprising fusion variants of FGF19 polypeptides |
US9751924B2 (en) | 2011-07-01 | 2017-09-05 | Ngm Biopharmaceuticals, Inc. | Methods of using compositions comprising fusion variants of FGF19 polypeptides for reducing glucose levels in a subject |
US11065302B2 (en) | 2011-07-01 | 2021-07-20 | Ngm Biopharmaceuticals, Inc. | Compositions comprising fusion variants of FGF19 polypeptides |
US10413590B2 (en) | 2011-07-01 | 2019-09-17 | Ngm Biopharmaceuticals, Inc. | Methods of using compositions comprising variants of FGF19 polypeptides for reducing body mass in a subject |
US9089525B1 (en) | 2011-07-01 | 2015-07-28 | Ngm Biopharmaceuticals, Inc. | Methods of using compositions comprising variants and fusions of FGF19 polypeptides for reducing glucose levels in a subject |
US9963494B2 (en) | 2012-11-28 | 2018-05-08 | Ngm Biopharmaceuticals, Inc. | Methods of using compositions comprising variants and fusions of FGF19 polypeptides for reducing glucose levels in a subject |
US10758590B2 (en) | 2012-11-28 | 2020-09-01 | Ngm Biopharmaceuticals, Inc. | Methods of using compositions comprising variants and fusions of FGF 19 polypeptides for treating diabetes |
US9290557B2 (en) | 2012-11-28 | 2016-03-22 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides |
US11066454B2 (en) | 2012-11-28 | 2021-07-20 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides |
US9878009B2 (en) | 2012-12-27 | 2018-01-30 | Ngm Biopharmaceuticals, Inc. | Methods of using compositions comprising variants and fusions of FGF19 polypeptides for modulating bile acid homeostasis in a subject having error of bile acid synthesis |
US11103554B2 (en) | 2012-12-27 | 2021-08-31 | Ngm Biopharmaceuticals, Inc. | Methods of using compositions comprising variants of FGF19 polypeptides for reducing bile acid synthesis in a subject having cirrhosis |
US9895416B2 (en) | 2012-12-27 | 2018-02-20 | Ngm Biopharmaceuticals, Inc. | Methods of using compositions comprising variants and fusions of FGF19 polypeptides for modulating bile acid homeostasis in a subject having cholestasis |
US9974833B2 (en) | 2012-12-27 | 2018-05-22 | Ngm Biopharmaceuticals, Inc. | Methods of using compositions comprising variants and fusions of FGF19 polypeptides for modulating bile acid homeostasis in a subject having pregnancy intrahepatic cholestasis |
US9273107B2 (en) | 2012-12-27 | 2016-03-01 | Ngm Biopharmaceuticals, Inc. | Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
US9878008B2 (en) | 2012-12-27 | 2018-01-30 | Ngm Biopharmaceuticals, Inc. | Methods of using compositions comprising variants and fusions of FGF19 polypeptides for modulating bile acid homeostasis in a subject having bile acid diarrhea or bile acid malabsorption |
US9889178B2 (en) | 2012-12-27 | 2018-02-13 | Ngm Biopharmaceuticals, Inc. | Methods of using compositions comprising variants and fusions of FGF19 polypeptides for modulating bile acid homeostasis in a subject having nonalcoholic steatohepatitis |
US9889177B2 (en) | 2012-12-27 | 2018-02-13 | Ngm Biopharmaceuticals, Inc. | Methods of using compositions comprising variants and fusions of FGF19 polypeptides for modulating bile acid homeostasis in a subject having primary sclerosing cholangitis |
US9925242B2 (en) | 2012-12-27 | 2018-03-27 | Ngm Biopharmaceuticals, Inc. | Methods of using compositions comprising variants and fusions of FGF19 polypeptides for treatment of nonalcoholic steatohepatitis |
US11564972B2 (en) | 2012-12-27 | 2023-01-31 | Ngm Biopharmaceuticals, Inc. | Methods of using compositions comprising variants of FGF19 polypeptides for treating primary biliary cirrhosis in a subject |
US10369199B2 (en) | 2013-10-28 | 2019-08-06 | Ngm Biopharmaceuticals, Inc. | Methods of using variants of FGF19 polypeptides for the treatment of cancer |
US11596676B2 (en) | 2014-01-24 | 2023-03-07 | Ngm Biopharmaceuticals, Inc. | Methods of treating nonalcoholic steatohepatitis comprising administering an anti-human beta klotho antibody or binding fragment thereof |
US10744191B2 (en) | 2014-01-24 | 2020-08-18 | Ngm Biopharmaceuticals, Inc. | Beta klotho-binding proteins and methods of use thereof |
US10093735B2 (en) | 2014-01-24 | 2018-10-09 | Ngm Biopharmaceuticals, Inc. | Beta-klotho binding proteins |
US10398758B2 (en) | 2014-05-28 | 2019-09-03 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions |
US11241481B2 (en) | 2014-06-16 | 2022-02-08 | Ngm Biopharmaceuticals, Inc. | Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
US10456449B2 (en) | 2014-06-16 | 2019-10-29 | Ngm Biopharmaceuticals, Inc. | Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
US10517929B2 (en) | 2014-10-23 | 2019-12-31 | Ngm Biopharmaceuticals, Inc. | Pharmaceutical compositions comprising FGF19 variants |
US11141460B2 (en) | 2014-11-07 | 2021-10-12 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders |
US10434144B2 (en) | 2014-11-07 | 2019-10-08 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders |
US10800843B2 (en) | 2015-07-29 | 2020-10-13 | Ngm Biopharmaceuticals, Inc. | Beta klotho-binding proteins |
US11667708B2 (en) | 2015-07-29 | 2023-06-06 | Ngm Biopharmaceuticals, Inc. | Anti-human beta klotho antibody or binding fragment thereof and methods of their use |
US10744185B2 (en) | 2015-11-09 | 2020-08-18 | Ngm Biopharmaceuticals, Inc. | Methods of using variants of FGF19 polypeptides for the treatment of pruritus |
US11370841B2 (en) | 2016-08-26 | 2022-06-28 | Ngm Biopharmaceuticals, Inc. | Methods of treating fibroblast growth factor 19-mediated cancers and tumors |
Also Published As
Publication number | Publication date |
---|---|
JP2006016323A (ja) | 2006-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006004076A1 (fr) | Matière bio physiologiquement active | |
Hino et al. | The generation of germline transgenic silkworms for the production of biologically active recombinant fusion proteins of fibroin and human basic fibroblast growth factor | |
US10493134B2 (en) | Compositions comprising collagen and PRP for tissue regeneration | |
Kambe et al. | Silk fibroin sponges with cell growth‐promoting activity induced by genetically fused basic fibroblast growth factor | |
CN104946656B (zh) | 一种人源碱性成纤维细胞生长因子、烟草叶绿体表达载体及生产方法 | |
JP2009011323A (ja) | ヘパリン結合能の亢進したポリペプチド変異体 | |
CN107188948A (zh) | 用于诱导组织再生的肽及其应用 | |
JPH07500968A (ja) | 組み換え型骨形態形成蛋白ヘテロダイマー、組成物および使用法 | |
CN102695525A (zh) | 用于蛋白质表达的具有未修饰和修饰核苷酸的组合的rna | |
CN109568671A (zh) | 一种水凝胶负载细胞的3d骨修复支架及其制备方法 | |
Wang et al. | Large-scale production of bioactive recombinant human acidic fibroblast growth factor in transgenic silkworm cocoons | |
WO2007073661A1 (fr) | Matieres de squelette de collagene activees et leurs facteurs speciaux de restauration active fusionnee | |
JP6699821B2 (ja) | 神経再生用移植材料、神経再生用移植材料の製造方法、及び神経再生用移植材料製造用キット | |
JP5645187B2 (ja) | 三重螺旋構造を有するタンパク質、およびその製造方法 | |
Wöltje et al. | Functionalized silk fibers from transgenic silkworms for wound healing applications: Surface presentation of bioactive epidermal growth factor | |
CN116813749B (zh) | 一种重组人源化iii型胶原蛋白及其制备方法和应用 | |
CN115521372A (zh) | 一种三螺旋重组人源化iii型胶原蛋白、制备方法及应用 | |
CN115521373A (zh) | 一种三螺旋重组人源化i型胶原蛋白、制备方法及其应用 | |
Zhang et al. | Expression and characterization of recombinant human VEGF165 in the middle silk gland of transgenic silkworms | |
Abpeikar et al. | Engineered cells along with smart scaffolds: critical factors for improving tissue engineering approaches | |
CN110950930B (zh) | 骨肽及其成骨生理活性确证方法与用途 | |
CN111424035A (zh) | 基于家蚕丝腺表达具有生物学活性的人结缔组织生长因子的方法及其产品和应用 | |
CN106256380A (zh) | 功能生物材料在制备促进动物脊髓全横断损伤修复的材料中的应用 | |
CN114605516B (zh) | 具有自组装特性和生物矿化功能的藤壶胶蛋白20k衍生多肽、其制备方法和应用 | |
WO2024016740A1 (fr) | Procédé de préparation basé sur la biosynthèse pour matériau structural du corps humain |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
122 | Ep: pct application non-entry in european phase |